GlassScriptPhysician profile
Gilberto Torres-Madriz
NPI 1518157601
$41,555.96
in general payments reported to CMS, 2019-2025
19 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $6,957 · 2021: $2,990 · 2022: $4,250 · 2023: $1,033 · 2024: $2,026 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Food and Beverage: $5,352 · Education: $20.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,590.00 |
| Food and Beverage | $5,351.83 |
| Education | $20.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16,393.44 | 2019-2020 | |
| Shionogi INC | $11,954.31 | 2021-2025 | Fetroja |
| Abbvie INC. | $6,283.04 | 2021-2025 | Avycaz, Dalvance |
| Merck Sharp & Dohme LLC | $1,201.13 | 2019-2025 | Zerbaxa, Pifeltro, Recarbrio |
| Gilead Sciences, INC. | $1,060.46 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $923.29 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Insmed, INC. | $802.62 | 2019-2025 | Arikayce |
| Paratek Pharmaceuticals, INC. | $552.68 | 2021-2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $548.05 | 2021-2025 | Xerava, Zevtera, Xacduro |
| Melinta Therapeutics, LLC | $334.66 | 2019-2025 | Rezzayo, Kimyrsa |
| Ferring Pharmaceuticals INC. | $333.54 | 2022-2025 | Rebyota |
| Janssen Biotech, INC. | $329.78 | 2019-2023 | Symtuza |
| Cumberland Pharmaceuticals, INC. | $193.12 | 2024-2025 | Vibativ |
| Aimmune Therapeutics, INC. | $150.23 | 2024-2025 | Vowst |
| Janssen Products, LP | $141.47 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $121.42 | 2024 | Mytesi |
| Comsort, INC | $100.00 | 2019 | |
| Theratechnologies INC. | $87.54 | 2022 | |
| Vyera Pharmaceuticals, LLC | $45.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gilberto Torres-Madriz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.